Literature DB >> 23581412

Terbinafine inhibits KSR1 and suppresses Raf-MEK-ERK signaling in oral squamous cell carcinoma cells.

B Li1, L Lu, M Zhong, X X Tan, C Y Liu, Y Guo, X Yi.   

Abstract

Terbinafine inhibits the proliferation of many types of cancer cells, but the underlying mechanism remains to be determined. By computer simulation, we found that kinase suppressor of Ras 1 (KSR1) is a possible target of terbinafine. Treatment of human oral squamous cell carcinoma (OSCC) KB cells with either terbinafine or siRNA to knockdown KSR1 reduced proliferation and induced apoptosis, which was accompanied by suppression of the Raf-MEK-ERK pathway. In vivo, KSR1 expression was significantly associated with the clinical staging of OSCC and the smoking habit of patients. Kaplan Meyer survival analysis demonstrated that the cumulative survival time of patients without KSR1 expression was significantly longer than those with KSR1 overexpression. Our data provide the basis for developing terbinafine to treat OSCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581412     DOI: 10.4149/neo_2013_052

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Ioly Kotta-Loizou; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Eougken Dana; Jose Rodriguez; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Tumour Biol       Date:  2014-03-30

2.  p38 Expression and Modulation of STAT3 Signaling in Oral Cancer.

Authors:  I Gkouveris; N Nikitakis; A Sklavounou
Journal:  Pathol Oncol Res       Date:  2018-03-21       Impact factor: 3.201

3.  JNK1/2 expression and modulation of STAT3 signaling in oral cancer.

Authors:  Ioannis Gkouveris; Nikolaos Nikitakis; Maria Karanikou; George Rassidakis; Alexandra Sklavounou
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

Review 4.  Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy.

Authors:  Yuheng Zou; Hongying Zhang; Feng Bi; Qiulin Tang; Huanji Xu
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

5.  The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.

Authors:  L Zhou; J Lyons-Rimmer; S Ammoun; J Müller; E Lasonder; V Sharma; E Ercolano; D Hilton; I Taiwo; M Barczyk; C O Hanemann
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

6.  Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Authors:  L Benhaim; W Zhang; T Wakatsuki; D Yang; A Gerger; P Bohanes; D Paez; F Loupakis; M J LaBonte; Y Ning; R El-Khoueiry; R Ladner; P Wilson; H Zhang; G Giamas; J Stebbing; H J Lenz
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

7.  High SQLE Expression and Gene Amplification Correlates with Poor Prognosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Lijun Fang; Weixian Liu; Yang Liu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.